Epitalon vs MOTS-c

How they differ

Each row below repeats what the two profiles cite. It is not a ranking or a recommendation.

Side by side

TopicEpitalonMOTS-c
What it is

A synthetic peptide of four amino acids (Ala-Glu-Asp-Gly). FDA treats it as a different substance from epithalamin, a pineal-gland extract it was modeled on.1

A naturally occurring 16-amino-acid peptide encoded in mitochondrial DNA. FDA’s evaluation covers synthetic free-base and acetate forms.2

FDA status

Not FDA-approved

Not an FDA-approved drug1

Not FDA-approved. FDA staff recommended in May 2026 against adding epitalon to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, epitalon acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,3,4

Is epitalon FDA-approved?

Not FDA-approved

Not an FDA-approved drug2

Not FDA-approved. FDA staff recommended in May 2026 against adding MOTS-c to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, MOTS-c acetate is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.2,3,4

Is MOTS-c FDA-approved?

HHS compounding policy, October 30, 2026

In the policy: one of the six peptides it lists.4

In the policy: one of the six peptides it lists.4

FDA compounding safety-risk page

Listed.

FDA’s compounding safety-risk page, last updated April 22, 2026, lists epitalon among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.5

The profile does not say whether the current page lists it.

HHS’s policy document states that MOTS-c was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.4,5

Kinds of studies cited

Limited human data

  • Small, short, or incompletely reported human study A 2021 randomized, placebo-controlled study in 40 women working night shifts that measured a melatonin breakdown product over 20 days. FDA notes it did not state whether it was blinded, did not measure sleep, and did not report safety data.1
  • Small, short, or incompletely reported human study A 2002 report in people with retinitis pigmentosa, an inherited eye disease, and a meeting abstract stating that epitalon had no side effects in elderly people without giving study details.1
  • Animal or laboratory research Studies in monkeys, rats and mice reporting changes in melatonin and cortisol levels and fewer spontaneous tumors in female mice. FDA found no animal studies that measured sleep.1

Animal and lab studies only

  • Animal or laboratory research Mouse and rat studies reporting less diet-induced weight gain, better insulin sensitivity, effects on bone, and less blood-vessel calcification. FDA notes that the studies did not test whether larger amounts produced larger effects.2
  • Animal or laboratory research A laboratory study reporting that MOTS-c is broken down quickly in human blood.2
Records collected

0 ClinicalTrials.gov records and 24 PubMed records collected

0 ClinicalTrials.gov records and 41 PubMed records collected

Area of study

Brain, nerves and sleep1

Metabolic and weight, Bone and growth2

Latest dated events
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists epitalon among six peptide substances used in compounding.3,4
  2. FDA’s Pharmacy Compounding Advisory Committee discusses epitalon.6
  3. FDA staff date their evaluation recommending that epitalon not be added to the 503A bulks list.1
  1. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists MOTS-c among six peptide substances used in compounding.3,4
  2. FDA’s Pharmacy Compounding Advisory Committee discusses MOTS-c.6
  3. FDA staff date their evaluation recommending that MOTS-c not be added to the 503A bulks list.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    FDA briefing document for epitalon ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    FDA briefing document for MOTS-c ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  4. 4
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026